Protocol Ledger

NCT05026749 · Phase III · RECRUITING

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

Interventional Phase III clinical trial protocol NCT05026749 sponsored by University of Alabama at Birmingham in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-27 Enrollment: 370 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05026749
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)370 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05026749
Protocol FieldVerified Registry Value
NCT IdentifierNCT05026749
Consolidated Lead SponsorUniversity of Alabama at Birmingham
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment370 participants (ESTIMATED)
Registered Start Date2022-02-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI